MN Healthcare

Brand: Mounjaro KwikPen
Strength: 10 mg per dose
Dosage form: Prefilled injection pen
Route: Subcutaneous injection
Drug class: Dual GIP / GLP-1 receptor agonist
Prescription: Required

✅ Uses (human medicine)

Prescribed for:

• Type 2 diabetes mellitus

• Obesity (as per local approval / off-label use)

⚙ How it works

• Decreases appetite

• Improves insulin secretion

• Slows gastric emptying

• Lowers blood sugar and promotes weight reduction

�� Dose information

• 10 mg is a higher maintenance dose

• Injected once weekly

• Dose is increased gradually from lower strengths

• Do not change dose without doctor advice

⚠ Common side effects

• Nausea

• Vomiting

• Diarrhea / constipation

• Abdominal pain

• Fatigue

• Loss of appetite

�� Warnings

Do NOT use in patients with:

• Medullary thyroid carcinoma

• MEN syndrome type 2

Use with caution if you have:

• History of pancreatitis

• Severe stomach disorders

• Kidney disease

• Concurrent insulin use (risk of hypoglycemia)

�� Storage

• Store in refrigerator 2–8°C

• Do not freeze

• Protect from light

• Do not use if solution appears cloudy or discolored

⏳ Shelf life

Usually up to 24 months from manufacturing date when stored refrigerated (2–8°C).

�� Legal status

Prescription-only medicine

Generic name: Tirzepatide
Strength: 5 mg per dose
Dosage form: Subcutaneous injection (pen / vial)
Drug class: Dual incretin receptor agonist
Prescription: Required

✅ Uses (human medicine)

Prescribed for:

• Type 2 diabetes – to control blood sugar

• Obesity – for medical weight-loss therapy (as per approval / off-label use)

⚙ How it works

Activates:

• GLP-1 receptor → lowers appetite, delays stomach emptying

• GIP receptor → improves insulin action

Result: better glucose control + weight loss.

�� Dose details

• 5 mg is a titration / maintenance dose, usually given
  once weekly by subcutaneous injection.

• Often started after 2.5 mg is tolerated.

• Dose escalation is doctor-directed.

⚠ Common side effects

• Nausea

• Vomiting

• Diarrhea / constipation

• Abdominal discomfort

• Fatigue

• Reduced appetite

�� Important warnings

Do NOT use if:

• Medullary thyroid carcinoma history

• MEN syndrome (type 2)

• Severe gut disorders or history of pancreatitis (needs supervision)

Use caution if:

• On insulin / sulfonylureas (low sugar risk)

• Kidney disease

�� Storage

• Refrigerated: 2°C – 8°C

• Do not freeze

• Protect from light

• Follow brand guidance after opening (room-temp limits apply)

�� Legal status

Prescription-only medicine

Brand: Mounjaro KwikPen
Strength: 12.5 mg per dose
Dosage form: Prefilled injection pen
Route: Subcutaneous injection
Drug class: Dual GIP / GLP-1 receptor agonist
Prescription: Required

✅ Uses (human medicine)

Prescribed for:

• Type 2 diabetes mellitus

• Obesity (as per approval / off-label)

⚙ How it works

• Suppresses appetite

• Improves insulin action

• Slows digestion

• Improves blood glucose control

�� Dose information

• 12.5 mg is a higher maintenance dose

• Injected once weekly

• Used only after tolerance to lower doses

• Adjustment only under medical supervision

⚠ Common side effects

• Nausea

• Vomiting

• Constipation or diarrhea

• Abdominal discomfort

• Fatigue

• Loss of appetite

�� Warnings

Do NOT use if:

• Medullary thyroid carcinoma

• MEN syndrome type 2

Caution in:

• Pancreatitis history

• Chronic kidney disease

• Severe intestinal disease

• Insulin users (hypoglycemia risk)

�� Storage

• Refrigerate at 2–8°C

• Do not freeze

• Protect from light

• Do not use if solution is cloudy

⏳ Shelf life

Up to 24 months from manufacturing date when stored cold (2–8°C).

�� Legal status

Prescription-only medicine

Brand: Mounjaro KwikPen
Strength: 15 mg per dose
Dosage form: Prefilled injection pen
Route: Subcutaneous injection
Drug class: Dual GIP / GLP-1 receptor agonist
Prescription: Required

✅ Uses (human medicine)

Prescribed for:

• Type 2 diabetes mellitus

• Obesity (where approved / off-label)

⚙ How it works

• Strong appetite suppression

• Improves insulin release and sensitivity

• Slows stomach emptying

• Lowers blood glucose and supports weight loss

�� Dose information

• 15 mg is the highest maintenance dose

• Injected once weekly

• Used only after gradual dose escalation

• Dose changes must be physician-guided

⚠ Common side effects

• Nausea and vomiting

• Diarrhea or constipation

• Abdominal discomfort

• Fatigue

• Reduced appetite

�� Warnings

Do NOT use if:

• Medullary thyroid carcinoma

• MEN syndrome type 2

Use with caution if you have:

• Pancreatitis history

• Kidney disease

• Severe gastrointestinal disorders

• Are using insulin or sulfonylureas (low sugar risk)

�� Storage

• Store in refrigerator 2–8°C

• Do not freeze

• Protect from light

• Do not use if liquid is cloudy or discolored

⏳ Shelf life

Typically up to 24 months from manufacturing date when kept refrigerated (2–8°C).

�� Legal status

Prescription-only medicine

Generic name: Tirzepatide
Strength: 5 mg in 0.5 mL (pre-filled pen or vial)
Route: Subcutaneous injection (abdomen, thigh, upper arm)
Prescription: Required

✅ Uses (human)

Prescribed for:

• Type 2 diabetes mellitus – blood-glucose control

• Obesity – weight-loss therapy (where approved / off-label)

⚙ How it works

Activates two receptors:

• GLP-1 → lowers appetite, slows gastric emptying, reduces blood sugar

• GIP → improves insulin sensitivity

Result: better glucose control and weight reduction.

�� Dosing

• 5 mg is usually given once weekly

• Typically used after starting with 2.5 mg

• Dose adjustments only by doctor

⚠ Common side effects

• Nausea

• Vomiting

• Diarrhea / constipation

• Abdominal pain

• Reduced appetite

• Fatigue

�� Warnings

Do not use in:

• Medullary thyroid carcinoma

• MEN syndrome type 2

Use caution in:

• Pancreatitis history

• Severe stomach disorders

• Patients on insulin / sulfonylureas (low sugar risk)

�� Storage

• Refrigerate 2–8°C

• Do not freeze

• Protect from light

• After first use, storage time at room temperature depends on brand

�� Status

Prescription-only medicine

Generic name: Tirzepatide
Strength: 7.5 mg per dose
Dosage form: Injectable solution (prefilled pen / vial)
Route: Subcutaneous injection
Drug class: Dual incretin receptor agonist
Prescription: Required

✅ Uses (human medicine)

Prescribed for:

• Type 2 diabetes mellitus

• Obesity (as approved or off-label)

⚙ How it works

• Reduces appetite and food intake

• Improves insulin response

• Slows stomach emptying

• Lowers blood glucose levels

�� Dose information

• 7.5 mg is a maintenance / escalation dose

• Usually given once weekly

• Dose increased only after tolerance of lower doses

⚠ Common side effects

• Nausea

• Vomiting

• Diarrhea / constipation

• Abdominal discomfort

• Fatigue

• Decreased appetite

�� Warnings

Do NOT use if:

• Medullary thyroid carcinoma

• MEN syndrome type 2

Use caution in:

• History of pancreatitis

• Kidney disease

• Patients on insulin or sulfonylureas

�� Storage

• Refrigerate at 2–8°C

• Do not freeze

• Protect from light

• Follow brand-specific room-temperature limits after opening

⏳ Shelf life

Typically 24 months from manufacturing date when kept refrigerated.

�� Legal status

Prescription-only medicine

Generic name: Tirzepatide
Strength: 2.5 mg in 0.5 mL
Dosage form: Subcutaneous injection (pen / vial)
Prescription: Required

✅ Uses (human medicine)

Prescribed for:

• Type 2 diabetes mellitus

• Obesity (as approved/off-label)

⚙ How it works

• Reduces appetite

• Improves insulin response

• Slows stomach emptying

• Stabilizes blood sugar levels

�� Dose information

• 2.5 mg is the starting (initiation) dose

• Injected once weekly

• Increased gradually by doctor if needed

⚠ Common side effects

• Nausea

• Vomiting

• Diarrhea / constipation

• Reduced appetite

• Fatigue

�� Warnings

Do not use if:

• Medullary thyroid carcinoma

• MEN type 2

Use caution in:

• History of pancreatitis

• Severe intestinal disease

• Concurrent insulin use

�� Storage

• Refrigerate 2–8°C

• Do not freeze

• Protect from light

• After opening: follow manufacturer guidance

�� Legal status

Prescription-only medicine

Generic name: Tirzepatide
Strength: 2.5 mg per dose
Form: Subcutaneous injection (prefilled pen / vial, depends on brand)
Drug class: Dual incretin receptor agonist
Prescription: Required

✅ Uses (human medicine)

Approved / prescribed for:

• Type 2 diabetes – to improve blood sugar control

• Obesity – for medical weight management (as per regulatory approval in many countries)

⚙ How it works

Tirzepatide activates two gut hormone receptors:

• GLP-1 → reduces appetite + lowers blood sugar

• GIP → improves insulin sensitivity

Result:
Lower glucose levels, reduced hunger, and weight loss.

�� Dose information

2.5 mg is a starting (initiation) dose, not a maintenance dose.

Typical schedule:

• 2.5 mg once weekly for 4 weeks (to reduce side effects),

• then increased by doctor to a higher dose if needed.

It is not injected daily.

⚠ Common side effects

Most occur early and reduce with time:

• Nausea

• Vomiting

• Diarrhea or constipation

• Reduced appetite

• Abdominal discomfort

• Fatigue